Technology area: Biotechnology & Pharmaceuticals
56 pending office actions • 20 clients • 52 examiners • 39 art units • 0 of 56 (0%) have an AI response strategy ready • 50 patents granted in the last 365 days
This profile covers Biotechnology & Pharmaceuticals and records 56 pending office actions. Its career record includes 1974 applications, placing the current docket within an established prosecution portfolio. The technology classification indicates work where scientific disclosure and claim support may be especially significant.
The resolved allowance rate is 84.04%, and the average is 4.27 office actions per allowance. These figures separately describe resolved outcomes and examination effort. Practitioners can use the combination to anticipate the importance of sustained response strategy while managing the active docket.
Based on the USPTO statutory response window for each pending office action. 19 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 19 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (5%) |
| §103 only | 21 (38%) |
| §102 only | 1 (2%) |
| §112 only | 2 (4%) |
| Double-patenting only | 2 (4%) |
| Double-patenting + other | 4 (7%) |
| Multi-statute (no §101) | 22 (39%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHHAY, BONIRATH | 3 | 62.5% | +0.0% |
| RODRIGUEZ, VICENTE M | 2 | 77.4% | +15.7% |
| THUESON, HANNA MARIE | 2 | 76.7% | +28.2% |
| ZACHARIA, RAMSEY E | 1 | 78.4% | +28.7% |
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
| THOMAS, KAREEN KAY | 1 | 77.1% | +17.1% |
| BUI, DUNG H | 1 | 77.8% | +25.5% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.8% | +41.2% |
| MEYERS, ELIZABETH ANNE | 1 | 22.2% | +93.3% |
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18104770 | SCANNING MULTIPLE LIDAR SYSTEM OUTPUT SIGNALS | THATCHER, CLINT A | 60d overdue |
| 18072666 | CONTROL OF SIGNAL CHIRP IN LIDAR SYSTEMS | CHILTON, CLARA GRACE | 50d overdue |
| 18026287 | HYBRID PROTOCOLS AND BARCODING SCHEMES FOR MULTIPLE SEQUENCING TECHNOLOGIES | DAUNER, JOSEPH G | 35d overdue |
| 18271829 | INHIBITOR FOR CHRONIC MYELOID LEUKEMIA STEM CELLS | CRAIGO, BAHAR ALAWI | 23d |
| 18297593 | RECOMBINANTLY ENGINEERED POLYPEPTIDES CAPABLE OF RECYCLING NONCANONICAL COFACTORS | LEE, JIA-HAI | 26d |
| 17584129 | METHODS AND THERAPIES FOR TREATING ATHEROSCLEROSIS AND/OR HYPERLIPIDEMIA USING OLIGOSACCHARIDES | OLSON, ANDREA STEFFEL | 35d |
| 18028740 | COMPOSITION AND METHODS FOR MODULATING TCF4 GENE EXPESSION AND TREATING PITT HOPKINS SYNDROME | THUESON, HANNA MARIE | 86d |
| 18860177 | OSMOLYSIS-BASED RECOVERY OF BIOMACROMOLECULES FROM ENGINEERED HALOTOLERANT MICROORGANISMS | CHHAY, BONIRATH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18904689 | POLYESTER RESIN CLOSURES FOR CONTAINERS | THOMAS, KAREEN KAY | 84d |
| 18028740 | COMPOSITION AND METHODS FOR MODULATING TCF4 GENE EXPESSION AND TREATING PITT HOPKINS SYNDROME | THUESON, HANNA MARIE | 86d |
| 19080642 | FLOOR TILE WITH TRANSFERRED GLAZE COATING LAYER AND PREPARATION METHOD THEREOF | ZACHARIA, RAMSEY E | — |
| 18940334 | CANCER THERAPY WITH LIVE ATTENUATED BACTERIA | JACKSON-TONGUE, LAKIA J | — |
| 18852444 | MEMBRANES INCORPORATED WITH POROUS POLYMER FRAMEWORKS | BUI, DUNG H | — |
| 18826093 | INJECTABLE HYDROGEL FOR SUSTAINED CO-DELIVERY OF AN ANTIGEN AND AN ADJUVANT, AND USES THEREOF | OGUNBIYI, OLUWATOSIN A | — |
| 18841637 | ENDOSOMAL CLEAVABLE HYDROPHILIC-MASKED CATIONIC CHARGE DELIVERY VEHICLES | MEYERS, ELIZABETH ANNE | — |
| 18595334 | DEVICE DETECTION SYSTEM | RODRIGUEZ, VICENTE M | — |
| Art Unit | Apps |
|---|---|
| 1645 | 8 |
| 3645 | 5 |
| 1758 | 2 |
| 3642 | 2 |
| 1632 | 2 |
| 1628 | 2 |
| 1638 | 2 |
| 1787 | 1 |
| 3736 | 1 |
| 1773 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19080642 | FLOOR TILE WITH TRANSFERRED GLAZE COATING LAYER AND PREPARATION METHOD THEREOF | BANFERT NEW MATERIALS CO., LTD. | ZACHARIA, RAMSEY E | 1787 | §102§103§112DP | Non-Final OA | — | Pending | Mar 14, 2025 |
| 18940334 | CANCER THERAPY WITH LIVE ATTENUATED BACTERIA | Prokarium Limited | JACKSON-TONGUE, LAKIA J | 1645 | §112DP | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18860177 | OSMOLYSIS-BASED RECOVERY OF BIOMACROMOLECULES FROM ENGINEERED HALOTOLERANT MICROORGANISMS | The Regents of the University of California | CHHAY, BONIRATH | 1645 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18904689 | POLYESTER RESIN CLOSURES FOR CONTAINERS | Origin Materials Operating, Inc. | THOMAS, KAREEN KAY | 3736 | §103 | Non-Final OA | 84d | Pending | Oct 02, 2024 |
| 18852444 | MEMBRANES INCORPORATED WITH POROUS POLYMER FRAMEWORKS | The Regents of the University of California | BUI, DUNG H | 1773 | §102§103 | Non-Final OA | — | Pending | Sep 28, 2024 |
| 18826093 | INJECTABLE HYDROGEL FOR SUSTAINED CO-DELIVERY OF AN ANTIGEN AND AN ADJUVANT, AND USES THEREOF | The Regents of the University of California | OGUNBIYI, OLUWATOSIN A | 1645 | §103 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18841637 | ENDOSOMAL CLEAVABLE HYDROPHILIC-MASKED CATIONIC CHARGE DELIVERY VEHICLES | The Regents of the University of California | MEYERS, ELIZABETH ANNE | 1611 | §102§103§112 | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18730594 | RAPID DIAGNOSTIC DRY REAGENT TEST FOR ANTIBIOTIC RESISTANCE, AND METHODS OF USE AND METHODS OF MAKING THEREOF | Bioamp Diagnostics, Inc. | CHHAY, BONIRATH | 1645 | §102§103§112 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18724564 | CYSTEAMINE AND/OR CYSTAMINE PRODRUGS | The Regents of the University of California | BAUER, BRIANNA LEE | §103§112 | Non-Final OA | — | Pending | Jun 26, 2024 | |
| 18720403 | CARBON FIXATION SYSTEM | Phase Biolabs Ltd. | SINGH, SATYENDRA K | 1657 | §103 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18716430 | COMBINATION CANCER THERAPY | Prokarium Limited | DUFFY, PATRICIA ANN | 1645 | §102§103§112Other | Non-Final OA | — | Pending | Jun 04, 2024 |
| 18664102 | DIGITAL MICROFLUIDIC SYSTEM FOR SINGLE-CELL ISOLATION AND CHARACTERIZATION OF ANALYTES | Illumina, Inc. | TSUI, YUNG-SHENG M | 1684 | §102§112DP | Non-Final OA | — | Pending | May 14, 2024 |
| 18644030 | IMAGING SYSTEM WITH INCREASED EFFICIENCY | Silc Technologies, Inc. | GARDINER, JOSH CHARLES | 3648 | §103§112 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18641237 | MASS SPECTROMETRY-CLEAVABLE HALOACETAMIDE-BASED CROSS-LINKERS AND USES THEREOF | The Regents of the University of California | RHOADES, DEREK JAMES | 1692 | §103§112DP | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18636709 | SILICON MOLD FOR HIGH TEMPERATURE COMPRESSION MOLDING AND PREPARATION METHOD THEREOF | Huatong Optical Technology (Zhejiang) Co., Ltd. | DEHGHAN, QUEENIE S | 1741 | §103Other | Final Rejection | 9d | Pending | Apr 16, 2024 |
| 18696817 | DETECTION OF BLADDER CANCER IN MALES | Randox Laboratories Ltd. | NGUYEN, HENRY H | 1758 | §102§103 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18611334 | PORTABLE LIQUID ANALYZER | VERITEQUE USA, INC. | SINES, BRIAN J | 1796 | §103Other | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18595334 | DEVICE DETECTION SYSTEM | Silc Technologies, Inc. | RODRIGUEZ, VICENTE M | 3642 | §102§103§112 | Non-Final OA | — | Pending | Mar 04, 2024 |
| 18684155 | ANTIGEN PRESENTING CELL/TARGET CELL HYBRIDOMA-DERIVED VACCINES | The Regents of the University of California | TRAN, KHOA NHAT | 1632 | §103§112 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18681457 | GENETICALLY ENGINEERED CELL-DERIVED VACCINES | The Regents of the University of California | CHHAY, BONIRATH | 1645 | §103§112Other | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18430592 | INTEGRATION OF LIDAR SYSTEM COMPONENTS | Silc Technologies, Inc. | NASER, SANJIDA IFFAT | 3645 | §103 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18290679 | PTPRS IN AUTOIMMUNITY | The Regents of the University of California | KRUSE, DAVID H | 1663 | §102 | Final Rejection | 28d overdue | Pending | Jan 19, 2024 |
| 18572651 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | Ldn Pharma Limited | VALENROD, YEVGENY | 1628 | §112 | Non-Final OA | 83d | Pending | Dec 20, 2023 |
| 18539251 | AMPLIFICATION OF SIGNALS IN IMAGING SYSTEMS | Silc Technologies, Inc. | DECARIA, MICHAEL ALEX | 4100 | §103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18284783 | DETECTION ASSAY | Randox Teoranta | HAQ, SHAFIQUL | 1678 | §103 | Final Rejection | — | Pending | Sep 28, 2023 |
| 18283652 | METHOD OF DETERMINING PROGNOSIS OF CHRONIC KIDNEY DISEASE | Randox Teoranta | SAOUD, CHRISTINE J | 1645 | §101§102§112 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18239086 | CHANGE OF RESOLUTION IN FIELD OF VIEW | Silc Technologies, Inc. | HUTCHENS, CHRISTOPHER D. | 3647 | §103 | Non-Final OA | — | Pending | Aug 28, 2023 |
| 18234826 | 2-S RIMANTADINE AND 2-R RIMANTADINE FOR TREATING CANCER | Toragen, Inc. | YOO, SUN JAE | 1621 | §103 | Final Rejection | 28d | Pending | Aug 16, 2023 |
| 18231114 | AUTOIMMUNE THERAPY | Ldn Pharma Limited | COPPINS, JANET L | 1628 | §103 | Non-Final OA | 83d | Pending | Aug 07, 2023 |
| 18273710 | NALTREXONE COMPOSITIONS | Ldn Pharma Limited | ARNOLD, ERNST V | 1613 | §103 | Non-Final OA | 49d overdue | Pending | Jul 21, 2023 |
| 18271829 | INHIBITOR FOR CHRONIC MYELOID LEUKEMIA STEM CELLS | Saga University | CRAIGO, BAHAR ALAWI | 1699 | §102§103§112 | Non-Final OA | 23d | Pending | Jul 11, 2023 |
| 18270730 | PROGRAMMABLE RNA EDITING IN VIVO VIA RECRUITMENT OF ENDOGENOUS ADARS | The Regents of the University of California | PENNINGTON, KATIE LEIGH | 1634 | §103 | Final Rejection | — | Pending | Jul 02, 2023 |
| 18037968 | METHODS FOR USE IN PREVENTATIVE HEALTHCARE | Randox Laboratories Ltd. | LUSI, ELLIS FOLLETT | 1677 | §101§112 | Final Rejection | — | Pending | May 19, 2023 |
| 18297593 | RECOMBINANTLY ENGINEERED POLYPEPTIDES CAPABLE OF RECYCLING NONCANONICAL COFACTORS | The Regents of the University of California | LEE, JIA-HAI | 1658 | §102§112 | Final Rejection | 26d | Pending | Apr 07, 2023 |
| 18028740 | COMPOSITION AND METHODS FOR MODULATING TCF4 GENE EXPESSION AND TREATING PITT HOPKINS SYNDROME | The Regents of the University of California | THUESON, HANNA MARIE | 1638 | §102§103 | Non-Final OA | 86d | Pending | Mar 27, 2023 |
| 18026287 | HYBRID PROTOCOLS AND BARCODING SCHEMES FOR MULTIPLE SEQUENCING TECHNOLOGIES | The Regents of the University of California | DAUNER, JOSEPH G | 1682 | §102§103§112 | Final Rejection | 35d overdue | Pending | Mar 14, 2023 |
| 18022630 | siRNA AND USE THEREOF | Ohara Pharmaceutical Co., Ltd. | SHIN, DANA H | 1635 | Other | Non-Final OA | — | Pending | Feb 22, 2023 |
| 18104770 | SCANNING MULTIPLE LIDAR SYSTEM OUTPUT SIGNALS | Silc Technologies, Inc. | THATCHER, CLINT A | 3645 | §102§103 | Final Rejection | 60d overdue | Pending | Feb 01, 2023 |
| 18100204 | IMMUNOMODULATORY OLIGOSACCHARIDES | The Regents of the University of California | BAKSHI, PANCHAM | 1623 | §103 | Non-Final OA | — | Pending | Jan 23, 2023 |
| 18006011 | GUN SHOT RESIDUE FIELD KIT | VERITEQUE USA, INC. | FRITCHMAN, REBECCA M | 1758 | §103 | Final Rejection | 16d overdue | Pending | Jan 19, 2023 |
| 18016432 | RECOMBINANT MICROORGANISMS | The Regents of the University of California | DICKENS, AMELIA NICOLE | 1645 | §112 | Non-Final OA | — | Pending | Jan 16, 2023 |
| 18097261 | OPTICAL BRIDGES FOR PHOTONIC INTEGRATED CIRCUITS | Silc Technologies, Inc. | TAVLYKAEV, ROBERT FUATOVICH | 2896 | §103 | Non-Final OA | 30d overdue | Pending | Jan 15, 2023 |
| 18076001 | ANTI-AGING DERMATOLOGICAL COMPOSITIONS | Dr. Sabrina Ltd. | WRIGHT, SARAH C | 1619 | §103 | Final Rejection | 7d | Pending | Dec 06, 2022 |
| 18074402 | ENGINEERED VASCULARIZED ORGANOIDS | The Regents of the University of California | THUESON, HANNA MARIE | 1638 | §103 | Non-Final OA | — | Pending | Dec 02, 2022 |
| 18072666 | CONTROL OF SIGNAL CHIRP IN LIDAR SYSTEMS | Silc Technologies, Inc. | CHILTON, CLARA GRACE | 3645 | §103§112 | Final Rejection | 50d overdue | Pending | Nov 30, 2022 |
| 17924480 | METHOD FOR PRODUCING REGENERATED T CELLS VIA IPS CELLS | Thyas Co. Ltd. | SPENCE, JENNIFER SUZANNE | 1633 | §103§112 | Non-Final OA | — | Pending | Nov 10, 2022 |
| 17924080 | VECTORS AND METHODS FOR IN VIVO TRANSDUCTION | Abintus Bio, Inc. | JACKSON III, WALTER | 1674 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2022 |
| 17970508 | IDENTIFICATION OF CHIRP RATES | Silc Technologies, Inc. | NAPIER, JAMES WILBURN | 3645 | §102§103 | Final Rejection | — | Pending | Oct 20, 2022 |
| 17912313 | SCREENING METHODS TO IDENTIFY SMALL MOLECULE COMPOUNDS THAT PROMOTE OR INHIBIT THE GROWTH OF CIRCULATING TUMOR CELLS, AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA | SCHLIENTZ, LEAH H | 1618 | §103 | Final Rejection | — | Pending | Sep 16, 2022 |
| 17858042 | IMAGING SYSTEM USING LIGHT SOURCE WITH TUNABLE ELECTRO-OPTICS | Silc Technologies, Inc. | RICHTER, KARA | 3645 | §103 | Final Rejection | — | Pending | Jul 05, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial84.0% of resolved applications prosecuted by Joseph R. Baker, Apc were allowed, across 1,974 applications in USPTO records.
4.27 office actions per allowed application on average.
56 pending office actions as of October 2026, for 20 clients, before 52 examiners in 39 art units.
